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INTRODUCTION
Bronchial asthma is a chronic airway inflammatory disor-
der, characterized by airway infiltration of inflammatory cells
such as eosinophils and T-lymphocytes, and progressive air-
flow obstruction (1). These cells are involved in a network of
various cytokines (2) and contribute to bronchial hyperre-
sponsiveness and structural changes (3). As a consequence,
enhanced attention has been paid to the structural changes
referred as airway remodeling (4-7) characterized by goblet
cell hyperplasia/hypertrophy (8), subepithelial collagen depo-
sition, and smooth muscle hyperplasia/hypertrophy. All these
changes were responsible for airway wall thickening, which
appears to be the basis of increased airway hyperresponsive-
ness (AHR) in chronic asthma (9). Recently, several animal
studies were performed to clarify the relation between airway
inflammation and remodeling, and furthermore their contri-
bution to AHR in chronic asthma, despite the fact that the
precise mechanisms and associations are unknown (10-15).
In the present study, we studied the kinetics of inflamma-
tory cell infiltration, specific IgE, IgG1, IgG2a response, cy-
tokine production in the airways, goblet cell hyperplasia,
airway fibrosis, and their association with AHR during chron-
ic (long time course) ovalbumin (OVA) challenge in sensi-
tized mice.
MATERIALS AND METHODS
Animal model
Specific pathogen-free female BALB/c mice were used as
a chronic asthma model when they reached 7 weeks of age.
The mice were housed in environmentally controlled specif-
ic-pathogen free conditions for 1 week prior to the study and
during the experiments. All animal experimental protocols
were approved by the Catholic University of Korea, Animal
Subjects Committee. Mice were actively sensitized by intra-
peritoneal injections of 100  g OVA (grade V; Sigma, St.
Louis, MO) together with 500  g aluminum hydroxide (Ald-
rich, Milwaukee, WI) in phosphate buffered saline (PBS) on
day 0 and day 14. From day 21, they were exposed to aero-
solized OVA (1% wt/vol diluted in sterile PBS) for 30 min
twice weekly. Different groups of mice were studied accord-
ing to the duration of antigen exposure: Group I (n=12), 4
weeks; Group II (n=12), 8 weeks; Group III (n=11), 12 weeks
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Time Sequence of Airway Remodeling in a Mouse Model of Chronic
Asthma: the Relation with Airway Hyperresponsiveness
During the course of establishing an animal model of chronic asthma, we tried to
elucidate the time sequence of airway hyperresponsiveness (AHR), airway inflam-
mation, airway remodeling, and associated cytokines. Seven-week-old female BALB/
c mice were studied as a chronic asthma model using ovalbumin (OVA). After sen-
sitization, mice were exposed twice weekly to aerosolized OVA, and were divided
into three groups depending on the duration of 4 weeks, 8 weeks, and 12 weeks.
At each time point, airway responsiveness, inflammatory cells, cytokines in bron-
choalveolar lavage fluids (BALF), serum OVA-specific IgE, IgG1, IgG2a, and his-
tological examination were carried out. AHR to methacholine, increased levels of
OVA-specific IgG1 and IgG2a, and goblet cell hyperplasia were continuously sus-
tained at each time point of weeks. In contrast, we observed a time-dependent dec-
rease in serum OVA-specific IgE, BALF eosinophils, BALF cytokines such as IL-
13, transforming growth factor-beta1, and a time-dependent increase in BALF pro-
matrix metalloproteinase-9 and peribronchial fibrosis. In this OVA-induced chronic
asthma model, we observed airway remodelings as well as various cytokines and
inflammatory cells being involved in different time-dependent manners. However,
increased airway fibrosis did not directly correlate with a further increase in airway
hyperresponsiveness.
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(Fig. 1). Control mice (n=8) were sensitized and then exposed
to PBS in the same manner. Mice of each experimental group
were then killed 24 hr after exposure to OVA or PBS aerosols
for 3 consecutive days. The aerosol was generated from a neb-
ulizer and was drawn into a dome shaped exposure chamber
where restrained animals were distributed evenly and circum-
ferentially.
Measurement of airway function
Before the mice were killed, airway responsiveness to me-
thacholine was measured. To assess the airway responsiveness,
we used a non-invasive whole body mouse plethysmograph
(Allmedicus, An Yang, Korea) to measure a derived index
named enhanced pause (Penh). Penh is a reasonable analogue
of airway responsiveness to a non-specific inhaled stimulus,
such as methacholine, which provides an accepted measure
for comparison between the experimental groups.
Bronchoalveolar lavage fluid (BALF) preparation
After determination of airway responsiveness, the animals
were killed for collection of BALF and histological exami-
nation. The right lung of each mouse was lavaged with 0.4
mL calcium- and magnesium-free PBS after the trachea was
cannulated and the left bronchus was tied. This procedure
was repeated three times (total volume; approximately 1.0
mL, recovery >80%). BALF from each animal was collected
in a plastic tube and cooled on ice, and centrifuged (2,000
rpm) at 4℃ for 7 min. The supernatants of BALF in each
experimental group were stored at -70℃ for determination
of IL-13, IFN-gamma, pro-matrix metalloproteinase-9 (pro-
MMP-9), tissue inhibitor of matrix metalloproteinase-1 (TI-
MP-1), and transforming growth factor-beta1 (TGF-beta1).
Cell pellets were resuspended in PBS, stained with trypan
blue, and the number of nucleated cells was counted in a
hematocytometer. A differential count was made on a smear
prepared with a cytocentrifuge and stained with Diff-Quik
solution of at least 400 cells.
Measurement of OVA-specific IgE, IgG1, and IgG2a
Bloods from each experimental group were collected, and
sera were obtained by centrifugation and stored at -70℃.
OVA-specific IgE, IgG1, and IgG2a were determined by
enzyme-linked immunosorbent assay (ELISA) as follows. One
hundred microliters of OVA (100  g/mL in PBS) was dis-
pensed into each well of a 96-well flat microtiter plate and
incubated overnight at 4℃. The antigen-coated plates were
washed three times with 0.05% PBS-Tween 20 buffer (wash-
ing buffer) and incubated with mice sera overnight at 4℃.
Plates were washed five times with washing buffer and incu-
bated with antimouse IgE (Pharmingen, San Diego, CA,
U.S.A.), IgG1 (Sigma, St. Louis, MO, U.S.A.), and IgG2a
(Sigma, St. Louis, MO, U.S.A.) antibody overnight at 4℃.
They were then washed further five times before adding cit-
ric acid-phosphate buffer containing 0.15 mg/mL of O-pheny-
lenediamine (Sigma, St. Louis, MO, U.S.A.). Color was devel-
oped at room temperature, and the reaction was stopped with
2.5 M sulfuric acid, which was measured at 492 nm. The
each antibody level was expressed as arbitrary unit (A.U.),
which was a relative value based on the standard mouse serum
that was sensitized and exposed to OVA in the same manner.
Measurement of cytokines in BALF
The amount of cytokine in the supernatant of BALF was
measured using enzyme immunoassay (R&D Systems, Min-
neapolis, MN, U.S.A. for IL-13, IFN-gamma, pro-MMP-9,
and TIMP-1, BioSource International, Camarillo, CA, U.S.A.
for TGF-beta1). Each sample was measured according to the
manufacturer’s recommendations. The detection limit of
each kit is 1.5 pg/mL for IL-13, 2 pg/mL for IFN-gamma,
8 pg/mL for pro-MMP-9, 2.1 pg/mL for TIMP-1, and 15.6
pg/mL for TGF-beta1.
Immunocytochemical staining for MMP-9 and TIMP-1
For immunocytochemistry of MMP-9 and TIMP-1, the
cytocentrifuge preparations of BALF cells were fixed with
4% paraformaldehyde for 5 min and incubated sequentially
in accordance with instructions for mouse MMP-9, TIMP-1
immunostaining kit (R&D Systems, Minneapolis, MN, U.S.A.).
Briefly, detection was based on the formation of the avidin-
biotin complex with primary antibodies that reacted with
antigens. Visualization was based on enzymatic conversion
of a chromogenic substrate 5-bromo-4-chloro-3′ -indolyphos-
phate p-toluidine salt (BCIP) and nitro blue tetrazolium chlo-
ride (NBT) into a colored black-purple precipitate by alka-
line phosphatase (AP) at the sites of antigen localization.
After immunostaining, the slides were counterstained with
Nuclear Fast Red (Vector Laboratories, Burlingame, CA,
U.S.A.). For the control, BALF cells from mice were treated
without the primary antibody, under the same condition.
Histological study
For each mouse, the left lung was removed and fixed in 4%
Fig. 1. Schematic representation of systemic sensitization and
provocation protocol in each group of mouse asthma model.
IP, intraperitoneal injection.
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paraformaldehyde and then embedded in paraffin. At that
time, the left lung of each mouse was equally sectioned into
three pieces from the apex of the lung. Hematoxylin and eosin
stains were performed for general morphology, periodic acid-
Schiff (PAS) stain for identification of goblet cells in the epi-
thelium, Masson’s trichrome stain for airway fibrosis, respec-
tively. For the study, the bronchioles in which the total length
of the epithelial basement membrane is 1.0-1.5 mm, were
selected.
To quantify the goblet cell hyperplasia, we used the method
described by Padrid et al. (16) with some modifications. Brie-
fly, the pathological changes were evaluated according to the
modified 5-point scoring system (grade 0-4) and were exp-
ressed by scores according to the percentage of the goblet cells
in the epithelial cells: grade 0 (no goblet cells); grade 1, <25%;
grade 2, 25-50%; grade 3, 51-75%; grade 4, >75%. The
mean scores of goblet cell hyperplasia in each mouse were
calculated.
The areas of airway fibrosis beneath the epithelial basement
membrane in the Masson’s trichrome stained tissue sections
were calculated using a Polaroid DMC1e digital microscope
color camera (Polaroid Corporation, Cambridge, MA, U.S.A.)
connected with computerized image analyzer program, Op-
timas (Media Cybernetics, Silver Spring, MD, U.S.A.). The
mean areas of subepithelial fibrosis in each mouse were cal-
culated.
Statistical analysis
Values are presented as mean±SEM. The significance bet-
ween saline-inhaled and OVA-inhaled animals was estimated
using the two-tailed Student’s t test. p values of less than 0.05
were considered to be statistically significant.
RESULTS
Airway responsiveness
To investigate the relation with airway remodeling, AHR
to methacholine was examined at each time point. Fig. 2
shows the dose response curve of airway responsiveness to
methacholine. In each OVA-exposed asthma group, airway
responsiveness to methacholine was significantly increased
compared with control group. But there was no significant
difference in AHR between the asthma groups.
Serum OVA-specific Immunoglobulins and BALF cytokines
The serum level of OVA-specific IgE was consistently in-
creased in each asthma group exposed to OVA for 4, 8, and
12 weeks as compared with that of control mice. The peak
level of OVA-specific IgE was reached at 4 weeks of OVA
exposure, and after that, the level was significantly decreased
according to the exposure duration.
All asthma groups produced detectable levels of OVA-
specific IgG1 and IgG2a in serum, but there was no differ-
ence between the asthma groups. In control group, serum
OVA-specific IgG1 and IgG2a were not detected.
In BALF, the amount of a Th2 cytokine, IL-13 was signif-
icantly increased in all asthma groups compared with con-
trol group. In asthma groups, the peaked IL-13 level at 4
weeks was decreased at 8, 12 weeks according to the dura-
tion of antigen exposure. In contrast, the level of a Th1 cyto-
kine, IFN-gamma showed no significant difference between
control and asthma groups. The amount of pro-MMP-9 and
TIMP-1 in BALF was significantly higher in asthma groups
than in control mice throughout the experiment. In asthma
groups, the pro-MMP-9 level was increased in time depen-
dent manner and reached its peak at 12 weeks after exposure.
In contrast, the TIMP-1 level in asthma groups showed no
significant difference according to the duration of antigen
exposure. The TGF-beta1 level in BALF was significantly
higher in asthma groups than in control mice, and the level
Fig. 2. Airway hyperresponsiveness to methacholine in each group
of mouse asthma model. Compared with the control group, asth-
ma groups showed significantly increased airway hyperrespon-
siveness for 12 weeks (*p<0.01 vs. control group).
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peaked at 4 weeks after exposure (Table 1).
Cellular response in BALF
A significant increase in the total number of BALF cells
from OVA challenged mice was observed in comparison with
control mice (Fig. 3). The increase in total cell numbers was
associated with a significant increase in eosinophils, lympho-
cytes and to a lesser degree, neutrophils throughout the exper-
iments. The increased eosinophils in Group I were signifi-
cantly decreased according to the duration of repeated OVA
challenge in Group II and Group III.
Immunocytochemical staining for MMP-9 and TIMP-1
Compared with control mice, MMP-9 and TIMP-1 expres-
sions were remarkable in all asthma groups. According to
the morphological criteria, these expressions were observed
in various kinds of cells including macrophages, eosinophils,
neutrophils, and lymphocytes (Fig. 4).
Goblet cell hyperplasia
For the morphometric measurements of goblet cell hyper-
plasia, the average number of 25 (range: 23 to 27) airways
were analyzed in each experimental group. The length of
peribronchial basement membrane showed no significant
differences in each experimental group; Control, Group I,
Group II, and Group III (1.27±0.26 mm, 1.28±0.39 mm,
1.27±0.25 mm, and 1.28±0.24 mm, respectively). All
asthma groups showed significant goblet cell hyperplasia
compared with the control group detected with PAS staining
(Fig. 5). All of the challenged mice but none of the controls
demonstrated severe goblet cell hyperplasia, but there were
no significant differences between asthma groups (Fig. 6).
Peribronchial fibrosis
For the morphometric measurements of peribronchial fibro-
sis, the average number of 28 (range: 21 to 33) airways were
analyzed in each experimental group. The length of peribron-
chial basement membrane showed no significant differences
in each experimental group; Control, Group I, Group II, and
Group III (1.26±0.27 mm, 1.26±0.28 mm, 1.26±0.21
mm, and 1.26±0.17 mm, respectively). All asthma groups
showed significantly increased peribronchial fibrosis com-
pared with the control group detected with Masson’s trich-
rome staining (Fig. 7). In asthma groups, peribronchial fibro-
sis was significantly increased according to the duration of
OVA exposure (Fig. 8).
DISCUSSION
Until now, methods to establish a animal model of bron-
chial asthma have been diverse because many laboratories
Control Group I Group II Group III
Serum, OVA-specific
IgE (A.U.) 0.28±0.08* 16.41±2.61
� 6.44±0.63
� 3.73±0.47
IgG1 (A.U.) Not detected 9.33±0.06 9.58±0.03 11.22±0.45
IgG2a (A.U.) Not detected 6.11±3.32 3.23±0.33 4.35±0.23
BALF cytokines
IL-13 (pg/mL) 8.1±1.3
� 70.9±10.7
� 25.7±1.9
‖ 19.9±1.3
IFN-gamma (pg/mL) 4.8±0.5 5.3±1.0 7.1±0.5 6.3±0.9
Pro-MMP-9 (pg/mL) 35.0±11.8* 391.6±140.8
¶ 1059.9±222.5 1247.6±300.2
TIMP-1 (pg/mL) 27.4±4.9* 335.0±31.5 269.1±28.1 354.1±75.7
TGF-beta1 (pg/mL) 112.2±18.6* 404.0±39.9
¶ 290.4±29.8 262.4±33.3
Table 1. Changes of serum OVA-specific immunoglobulin productions and BALF cytokine levels in each group of mouse asthma model
*p<0.01 vs. Group I, Group II, and Group III; 
� p<0.01 vs. Group II and Group III; 
� p<0.01 vs. Group III; 
�p<0.05 vs. Group I, Group II, and Group III; 
‖p<
0.05 vs. Group III; 
¶p<0.05 vs. Group II and Group III.
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Fig. 3. Changes of inflammatory cells in bronchoalveolar lavage
fluid in each group of mouse asthma model. Compared with the
control group, asthma groups showed significantly increased in-
flammatory cells including eosinophils, lymphocytes and neutro-
phils (*p<0.01). In the asthma groups, eosinophils were significant-
ly decreased after prolonged OVA inhalations for 8 weeks and 12
weeks (
� p<0.01).
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*performed different animal experiments according to the
type and dose of antigen, duration of antigen exposure, route
of antigen administration, the use of systemic sensitization,
animal strain, and method of measuring AHR (10-15).
Human asthmatic airway shows chronic change, so called
airway remodeling. However, most of the experimental ani-
mals for human asthma studies use an acute animal model,
which lacks the airway remodeling characteristics of human
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Fig. 4. Photomicrographs of MMP-9 (I) and TIMP-1 (II) immunoreactivity in the bronchoalveolar lavage cells of each group of mouse asth-
ma model (×400): (A) Control group, (B) Group I (4 weeks OVA inhalation), (C) Group II (8 weeks OVA inhalation), (D) Group III (12 weeks
OVA inhalation). Positive staining cells expressed blue color in their cytoplasm. Compared with the control group, MMP-9 and TIMP-1 expres-
sions were obvious in asthma groups.
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IIchronic asthma. Recently, some animal researches used a chro-
nic asthma model that resembled airway remodeling of human
chronic asthma (10, 14). However, after chronic antigen expo-
sure, the animal easily developed immune tolerance, and
chronic asthma model was difficult to maintain for a long time
(13, 17).
In this study, we established a clinically relevant experi-
mental animal model that replicated most of the features of
chronic human asthma. Furthermore, we could observe the
time sequence of airway inflammation and remodeling as
well as AHR from 4 to 12 weeks of allergen exposure. Vari-
ous cytokines as well as inflammatory cells were related with
airway inflammation and remodeling in a time-dependent
manner in this study protocol.
Total inflammatory cell counts in BALF decreased after a
prolonged exposure. In Group III, total inflammatory cell
counts showed a significant decrease compared with Group
I. The reason could be thought that generally, not acute but
chronic inflammation tends to decrease the number of infla-
mmatory cells. The eosinophils in BALF also decreased after
prolonged exposure, but the neutrophils and the lymphocytes
increased gradually which showed that chronic exposure of
antigen was associated with the increased lymphocytes and
neutrophils. Therefore, it might be thought that neutrophils
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Fig. 5. Photomicrographs of PAS stain of lung tissue in each group
of mouse asthma model (×100): (A) Control group, (B) Group I
(4 weeks OVA inhalation), (C) Group II (8 weeks OVA inhalation),
(D) Group III (12 weeks OVA inhalation). Compared with the con-
trol group, asthma groups showed increased goblet cell hyper-
plasia, and furthermore airway obstructions were developed due to
mucus secretion and fibrosis of the bronchial wall (E).
A B
C
E
Dand lymphocytes as well as eosinophils are involved in chron-
ic allergic airway inflammation. Kamath et al. (18) suggest-
ed the important role of neutrophils in the allergic airway
inflammations, and presented data that supported the cur-
rent renewed interest in the neutrophil as a primary driver
of airway inflammation, particularly in the most severe forms
of asthma. Further studies, especially the principal drivers
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Fig. 7. Photomicrographs of Masson’s trichrome stain of lung tissue in each group of mouse asthma model (×100): (A) Control group, (B)
Group I (4 weeks OVA inhalation), (C) Group II (8 weeks OVA inhalation), (D) Group III (12 weeks OVA inhalation). Peribronchial fibrosis
developed after prolonged OVA inhalations.
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Fig. 8. Changes of peribronchial collagen deposition in each group
of mouse asthma model. Compared with the control group, asth-
ma groups showed significantly increased peribronchial fibrosis
(*p<0.01). In the asthma groups, Group II showed more signifi-
cant increase of peribronchial fibrosis than Group I (
� p<0.01), and
Group III showed more significant increase of peribronchial fibro-
sis than Group II (
� p<0.05).
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Fig. 6. Changes of goblet cell hyperplasia in each group of mouse
asthma model. The hyperplasia of goblet cells in the epithelial lin-
ing was expressed by a score according to the percentage of the
goblet cells in the epithelial cells: grade 0, no goblet cells; grade
1, <25%; grade 2, 25-50%; grade 3, 51-75%; grade 4, >75% or
total bronchial obstruction due to mucus. Compared with the con-
trol group, asthma groups showed significantly increased goblet
cell hyperplasia (*p<0.01). However, there were no significant
differences between asthma groups.190 S.J. Kim, C.H. Kim, J.H. Ahn, et al.
of neutrophil influx into asthmatic airways, the quantifica-
tion of neutrophil trafficking, and its therapeutic applications
would be needed more on the exact role of neutrophils (18,
19). In the present study, the eosinophils in BALF were dec-
reased significantly after a prolonged exposure, but the AHR
was maintained, suggesting that eosinophils were not the
only effecter cells, but neutrophils, lymphocytes, and other
factors might have been involved in the AHR.
OVA-specific IgG1 and IgG2a were significantly increased
in the asthma groups compared with the control group, which
suggested that the Th1 immune response as well as the Th2
immune response were involved in allergic inflammation.
These results were similar to those of mouse asthma model
by Tanaka et al. (20), in which IgG1 showed a significant
increase and IgG2a showed an increased tendency compared
with control mice.
The Th2 cytokine IL-13 in BALF was increased in all as-
thma groups compared with the control group, and after a
peak level at the 4 weeks exposure, it decreased gradually at
the 8 and 12 weeks exposure, which was reverse with the
degree of peribronchial fibrosis.
Goblet cell hyperplasia developed remarkably as early as
4 weeks of OVA exposure, and was maintained in the same
potency to 12 weeks of OVA exposure. However, peribron-
chial fibrosis occurred only mildly in 4 weeks of OVA expo-
sure, although it progressed severely in a time-dependent
manner. Goblet cell hyperplasia and peribronchial fibrosis
are the main components of airway remodeling, but each
expressed different patterns in a time-dependent manner. In
the pathogenesis of airway mucus hypersecretion, Morcillo
et al. (21) reviewed that a distinct mucus hypersecretory phe-
notype may be present in asthma. Overexpression of MUC-
5AC, MUC5B and Muc2 has been associated in asthma secre-
tions. Activation of epidermal growth factor receptor appears
to be the central part in transducing many different stimuli,
including oxidative stress, proteases and T-helper-2 derived
cytokines such as IL-4, IL-5, IL-9, and IL-13. Among the
T-helper-2 derived cytokines, IL-13 is probably the primary
regulator of mucus hyperplasia in vivo (22). In contrast to
airway mucus hypersecretion, collagen I, III, and V; fibro-
nectin; and tenascin-C are deposited in the pathogenesis of
peribronchial fibrosis. Extensive evidence supports the piv-
otal role of IL-4 and IL-13 in peribronchial fibrosis; howev-
er the precise mechanism remains unclear (23). Therefore, it
might be thought that goblet cell hyperplasia and peribron-
chial fibrosis could have different expressive patterns accord-
ing to the time sequence due to their different pathogenesis.
AHR was continuously noted from 4 weeks to 12 weeks
of OVA exposure, but it did not progress after repeated OVA
exposure. Furthermore, at 8 or 12 weeks of OVA exposure,
it did not show a significant difference in some of methacho-
line concentrations compared with the control group. Thus,
we could know that further increase of peribronchial fibrosis
did not contribute to further increase of AHR, at least in this
model. We could suggest several possible mechanisms under-
lying this discordance between AHR and peribronchial fibro-
sis. First, AHR was developed by diverse relationships such
as inflammatory cells including the eosinophils, the cytokine
balance, the components of airway remodeling including
bronchial epithelium, submucosal changes, smooth muscle
hyperplasia/hypertrophy, angiogenesis. Thus, AHR could
not be determined by only one element among them. Second,
according to the study of Palmans et al. (24) with Brown
Norway rat, airway fibrosis increased in a time-dependent
manner, but AHR was abolished at 12 weeks exposure. They
suggested that airway fibrosis could have made thinner air-
way thickness, which led to decreased AHR.
In this study, Pro-MMP-9 and TIMP-1 in BALF were also
increased in the asthma groups compared with the control
group, which was consistent in other human and animal asth-
ma studies, suggesting that both MMP-9 and TIMP-1 con-
tribute to tissue remodeling (25-29). The balance between
MMP-9 and TIMP-1 may be critical in extracellular matrix
remodeling. An excess of TIMP-1 over MMP-9 has been
associated with chronic airflow obstruction, but the mecha-
nisms underlying this association remain unknown. In this
experiment, as the peribronchial fibrosis progressed, TIMP-1
levels were maintained relatively constant, but pro-MMP-9
showed a further increase due to the prolonged antigen inha-
lation. This result could be explained by the previous report
of Cho et al. (30) that they showed MMP-9 and TIMP-1 had
different expression patterns according to the source of ana-
tomical sites in the remodeled airway. MMP-9 but not TIMP-
1, was expressed in airway epithelium, whereas both MMP-
9 and TIMP-1 were expressed in peribronchial inflammato-
ry cells. In this experiment, we examined MMP-9 and TIMP-
1 levels in BALF that manifested mostly the airway epithe-
lium, the main source of MMP-9 but not of TIMP-1. In addi-
tion, we measured pro-MMP-9 levels, which could not dis-
play the active form of MMP-9.
In conclusion, we established a mouse model of chronic
asthma that maintained the airway and systemic inflamma-
tion for 12 weeks, which may contribute to the development
of airway remodeling. Chronic inflammatory cells, IgE, Th1
and Th2 cytokines, MMP-9 and TIMP-1 were involved con-
tinuously with different-time dependent manners. Airway
hyperresponsiveness could not be determined with a single
factor such as peribronchial fibrosis.
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